Company Filing History:
Years Active: 1979-1990
Title: Innovator Spotlight: Fritz Elsinger - Revolutionizing Pathogen Inactivation in Blood Plasma
Introduction: Fritz Elsinger, a brilliant inventor based in Vienna, Austria, has made significant contributions to the field of biomedical engineering with his groundbreaking work in pathogen inactivation in blood plasma products.
Latest Patents: Among Fritz Elsinger's impressive portfolio of inventions, his latest patents stand out. He has developed a method of inactivating reproducible filterable pathogens in blood plasma products by utilizing elevated temperatures. This innovative process involves heat treating the blood plasma products in a solid state within a closed inactivation container, in the presence of specific amounts of water and organic compounds. The unique combination of conditions ensures the effective inactivation of pathogens while preserving the integrity of the blood plasma products.
Career Highlights: Fritz Elsinger is currently affiliated with Immuno Aktiengesellschaft Fur Chemisch-medizinische Produkte, a renowned company in the field of biomedical research and development. His expertise and dedication have played a pivotal role in advancing the techniques for pathogen inactivation in blood products, leading to safer and more reliable biomedical products for global healthcare systems.
Collaborations: Throughout his career, Fritz Elsinger has collaborated with esteemed professionals in the industry. Some of his notable coworkers include Johann J Eibl and Otto Schwarz, who have contributed to the success of his innovative projects. Together, they have brought forth cutting-edge solutions that have reshaped the landscape of biomedical engineering.
Conclusion: Fritz Elsinger's relentless pursuit of excellence and his passion for innovation have positioned him as a trailblazer in the field of pathogen inactivation in blood plasma products. His dedication to advancing healthcare technologies underscores his commitment to improving the quality and safety of biomedical products for the benefit of society as a whole.